Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results (Q30886032)

20 August 2017

1 reference

14 September 2020

Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results (English)

1 reference

lung small cell carcinoma

20 August 2017

1 reference

14 September 2020

1 reference

14 September 2020

phase III clinical trial

1 reference

19 September 2019

1 reference

14 September 2020

Isao Oze

1

0 references

Mitsune Tanimoto

series ordinal

8

object named as

Mitsune Tanimoto

1 reference

20 August 2017

3

Katsuyuki Kiura

1 reference

20 August 2017

2

Katsuyuki Hotta

1 reference

20 August 2017

6

Yoshiro Fujiwara

1 reference

20 August 2017

5

Nagio Takigawa

1 reference

20 August 2017

4

Nobuaki Ochi

1 reference

20 August 2017

7

Masahiro Tabata

1 reference

PMC publication ID

2773043

20 August 2017

language of work or name

English

0 references

publication date

13 November 2009

5 references

20 August 2017

28 February 2019

3 April 2019

19 September 2019

14 September 2020

5 references

20 August 2017

28 February 2019

3 April 2019

19 September 2019

14 September 2020

4

1 reference

20 August 2017

11

1 reference

20 August 2017

e7835

1 reference

Creative Commons Attribution 4.0 International

20 August 2017

4 references

28 February 2019

3 April 2019

19 September 2019

on focus list of Wikimedia project

14 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Small cell lung cancer: have we made any progress over the last 25 years?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Prophylactic cranial irradiation in extensive small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Small cell lung cancer. State-of-the-art therapy 1994.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Keynote address on biostatistics and data retrieval.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Chemotherapy of small cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

14 July 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0007835

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0007835

Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0007835

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0007835

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773043

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

25 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19915681

12 December 2020

inferred from PubMed ID database lookup

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19915681

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1371/JOURNAL.PONE.0007835

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a4w26ldmfje35fsdse2gj4fxpm

30 July 2022

release_a4w26ldmfje35fsdse2gj4fxpm

ADS bibcode

2009PLoSO...4.7835O

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a4w26ldmfje35fsdse2gj4fxpm

30 July 2022

https://api.fatcat.wiki/v0/release/a4w26ldmfje35fsdse2gj4fxpm

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/a4w26ldmfje35fsdse2gj4fxpm

PubMed publication ID

1 reference

30 July 2022